The American Cancer Society estimates that about 67,440 Americans (34,950 men and 32,490 women) will be diagnosed with ...

A rapid nanosensor assay that measures serum protease cleavage of a target-probe nanosensor can identify pancreatic du ...

Pancreatic cancer is one of the deadliest types of cancer, with fewer than 13% of people diagnosed with it surviving for more ...

A new study from Memorial Sloan Kettering Cancer Center shows good results for patients with pancreatic cancer. They used a ...

A new type of mRNA vaccine, added to standard cancer treatment, could help some patients with pancreatic cancer live longer.

As few as one in ten people survive pancreatic cancer five years after their diagnosis — making it the most difficult cancer to survive. The survival rate five years after diagnosis is 6-14%, but ...

Recent positive lab confirmation of Smart mRNA functionality is a tremendous milestone for the Company. This marks a ...

Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional ...

Several ASX-listed healthcare companies with low market caps are making strides in tackling cancer,  a leading cause of death ...

Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...

The study developed a noninvasive detection method based on serum protease activity, leveraging the increased protease activity in the peripheral blood of patients with PDAC. Researchers screened a ...

Pancreatic cancer remains one of the deadliest forms of cancer, with an alarming 90% mortality rate among diagnosed patients.